News | September 01, 2021
Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpg)
As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Self-collection devices designed for ease of use and safety
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Aashka Hospitals has entered into a non-binding agreement for its proposed tie-up with Vaidehi—Backbone hospital, Rajkot
Acne affects up to 50 million Americans annually. The last FDA approval of an acne drug with a new MOA occurred nearly 40 years ago
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Subscribe To Our Newsletter & Stay Updated
